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Background: The interaction of HIV-1 and target cells involves sequential binding of the viral gp120 Env protein to
the CD4 receptor and a chemokine co-receptor (either CCR5 or CXCR4). CCR5 antagonists have proved to be an
effective salvage therapy in patients with CCR5 using variants (R5) but not with variants capable of using CXCR4
(×4) phenotype. Thus, it is critically important to determine cellular tropism of a country’s circulating HIV strains
to guide a management decision to improve treatment outcome. In this study, we report the prevalence of R5
and ×4 HIV strains in 45 proviral DNA massively parallel sequencing “MPS” data from recently infected Brazilian
blood donors.
Methods: The MPS data encompassing the tropism-related V3 loop region of the HIV‐1 env gene was extracted
from our recently published HIV-1 genomes sequenced by a paired-end protocol (Illumina). HIV‐1 tropism was
inferred using Geno2pheno[coreceptor] algorithm (3.5 % false-positive rate). V3 net charge and 11/25 rules were also
used for coreceptor prediction.
Results: Among the 45 samples for which tropism were determined, 39 were exclusively R5 variants, 5 ×4 variants,
and one dual-tropic or mixed (D/M) populations of R5 and ×4 viruses, corresponding to 86.7, 11.1 and 2.2 %,
respectively. Thus, the proportion of all blood donors that harbor CXCR4-using virus was 13.3 % including
individuals with D/M-tropic viruses.
Conclusions: The presence of CCR5-tropic variants in more than 85 % of our cohort of antiretroviral-naïve blood
donors with recent HIV-1 infection indicates a potential benefit of CCR5 antagonists as a therapeutic option in Brazil.
Therefore, determination of viral co-receptor tropism is an important diagnostic prerequisite.Background
The interaction of human immunodeficiency virus type
1(HIV-1) and target cells involves sequential binding of
the viral gp120 Env protein to the CD4 receptor and a
chemokine co-receptor [1]. The high selection pressures
exerted on the viral gp120 molecule explain why the
HIV-1 viral populations have very high genetic diversity.* Correspondence: sabyem_63@yahoo.com
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unless otherwise stated.Early after infection, HIV-1 variants are largely or exclu-
sively bind to β-chemokine co-receptor CCR5 in con-
junction with CD4 molecules; such variants are termed
‘R5 viruses’ [2]. These viruses are non-syncytium-
inducing isolates and do not replicate in T-cell lines, but
replicate well in macrophages and are known as macro-
phage tropic strains. T-cell line-tropic HIV-1 viruses
using another α-chemokine receptor, CXCR4, called ×4
variants while dual tropic or mixed (D/M) populations
can interact with both CCR5 and CXCR4 coreceptors in
the fusion process [3]. The emergence of ×4 viruses and
D/M isolates generally occur at the later stage of infec-
tion and are consistently associated with increased sever-
ity of disease in roughly half of all persons infected withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mining coreceptor tropism before initiating treatment
with the CCR5 coreceptor blocker maraviroc which has
exclusive activity against R5 viruses [7, 8]. HIV-1 tropism
may be determined by phenotypic or genotypic assays.
Phenotypic testing assess the ability of pseudoviruses
carrying the entire cloned env gene from a patient’s virus
to infect CCR5 or CXCR4 reporter cell-lines that also
express CD4 molecules [9]. Although this approach has
demonstrated good sensitivity and correlates well with
clinical outcome [7], phenotypic testing are complex to
perform, prohibitively expensive, and time-consuming. It
may also be inferred genotypically from the 35-amino-
acid V3 loop region of the viral envelope protein, gp120
sequence [10]. Emerging data from several studies indi-
cate that genotypic approach has several advantages over
the phenotypic assay that include a low cost, simpler
technical demands, faster turnaround time, and more
suitable to a large series compared with phenotypic tropism
testing [11, 12]. Moreover, genotypic predictors proved to
be highly concordant with phenotype data and can reliably
be used to determine viral tropism particularly in
treatment-experienced patients [8, 12, 13]. Previous studies
generally indicated that CXCR4-using viruses carry posi-
tively charged amino acids in the V3 loop, while CCR5-
tropic viruses do not [14, 15]. In a clinical setting, detection
of ×4 variants at low concentrations is considered import-
ant because they may potentially emerge during therapy
with a CCR5 antagonist. To improve the laboratory de-
tection sensitivity of ×4 minority species in aviremic
patients, the European Consensus Group guidelines rec-
ommended generation of sequences through independent
triplicate PCR amplification and/or by deep sequencing
technology [12, 16].
Despite the fact that Maraviroc has been used in Brazil
since 2007, few data are available about its efficacy during
routine use. Recently, Alencar et al. [17] found that 27.5 %
of samples from patients failing previous antiretroviral
therapy harbored one or more mutations that confer some
degree of susceptibility to maraviroc. In another study,
Araújo and coworkers [18] reported that most of the
resistance-associated mutations in ARV-naïve patients
occur in subtype C compared with subtype B strains.
Here, we report the prevalence of R5, ×4, and D/M
variants of HIV-1 from massively parallel sequencing
“MPS” proviral data generated during the early phase of
HIV-1 infection in a group of first-time Brazilian blood do-
nors. Although plasma HIV-1 RNA has been widely used
to determine the viral tropism the proviral PBMC DNA se-
quence can contain a variety of multiple archived genomes
that are not present in plasma. This, combined with the
stability of DNA compared with RNA, and the fact that
HIV DNA recovered from the proviral compartment can
reliably be used as an alternative to RNA tropism testing[19–22] influenced our decision to use proviral DNA in
this study.
Methods
Previously, we had described the genetic diversity of
HIV-1 using partial (n = 6) and near full-length genomes
(NFLG) sequence (n = 39) of human immunodeficiency
virus Type 1 provirus deep sequencing data from re-
cently infected donors at four blood centers participating
in the Retrovirus Epidemiology Donor Study (REDS-II)
International Program in Brazil [23]. Samples were
classified by less-sensitive (LS) or “detuned” enzyme im-
munoassay (Vironostika HIV-1 MicroElisa; bioMérieux,
Durham, NC) or an LS chemiluminescent immunoassay
(Vitros HIV-1/2 Assay; Ortho Diagnostics, Rochester,
NY) as recently infected at the time of donation based
on antibody levels consistent with recent seroconversion
(infected for <170 days) as previously described [24].
None of the participants received antiviral treatment
before. All study subjects provided written informed
consent. The study was approved by the local ethical
review committee of participating institutions as well as
the REDS-II collaborating centers (Blood Systems
Research Institute/University of California at San
Francisco, San Francisco, CA) and data coordinating
center (Westat, Inc.) in the United States.
Extraction of reads spanning the V3 region from HIV MPS
In this study, a sub-library of the env V3 population
sequence derived from each sample was created by map-
ping the raw MPS short reads to their corresponding V3
consensus sequence (Sequences positions: 210 to 315
[GenBank accession no. K03455] in standard reference
HXB2) using the CLC Genomics Workbench version
7.0.4 (CLC Bio, Aarhus, Denmark). To avoid artificial
generation of in silico chimeras through assembly and to
evade inflating the diversity estimates of the V3 region,
the analysis was restricted to individual paired-end reads
that encompass the complete V3 region from each data-
set. The reads were aligned, truncated and translated for
genotyping. Prior to the determination of viral tropism,
the MPS data were filtered out by the presence of frame
shifts, stop codons, and base-call ambiguity.
Determination of HIV-1 coreceptor tropism
HIV-1 co-receptor tropism was assessed from the filtered
V3 MPS data using the new prediction tool geno2pheno-
C_NGS-Sanger implemented in the Geno2Pheno [core-
ceptor] (http://coreceptor.bioinf.mpi-inf.mpg.de/), which
uses support vector machine technology. To minimize the
number of false predictions of CXCR4 tropic sequences as
CCR5 tropic, tropism was inferred using cutoffs optimized
and validated in the maraviroc treatment-experienced tri-
als and A4001029 clinical trials [16, 25]. Therefore, ×4 or
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quences had a prediction FPR result of ≤ 3.5 % (3.5 %
probability of classifying an R5 virus falsely as ×4) or the
11/25 rule [26] predicted a ×4 virus, otherwise, they
were considered CCR5-tropic viruses. The detection
threshold of minor ×4 variants varied according to the
number of extracted full-length reads of V3 for each
sample. Moreover, the overall net charge (NC) of V3
amino acid (R +K −D − E) were assigned to each sequence
fragment to predict HIV-1 tropism [27, 28]. Sequences with
NC values <5.0 were classified as R5, whereas sequences
with NC values ≥ 5.0 were classified as ×4.
Nucleotide distance analysis
The intra-host viral genetic diversities of the V3 nucleo-
tide sequences were computed from all available deep
sequences in each clinical sample using the maximum
composite likelihood in MEGA version 6 [29].
Nucleotide sequence accession numbers
The sequencing data have been uploaded to zenodo
https://zenodo.org/ (DOI: 10.5281/zenodo.14666).
Results
The near full-length genomes and/or larger fragments of
the 45 V3 MPS data used in this study have recently
been described for their genetic variability [23]. This
analysis indicated that 28 (62.2 %) were subtype B se-
quences, 11 (24.4 %) BF1 recombinants, 2 (4.4 %) BC
recombinants, 1 (2.2 %) were BC and BCF1 each, 1
(2.2 %) CRF45_cpx, and 1 (2.2 %) were the newly de-
scribed CRF70_BF1 [30]. The tropism predictions, FPR
values, and V3 net charges are shown in Table 1. The
datasets of the V3 sequence extracted from the NFLGs
ranged from 7 sequences in patient 10BR_SP048 to
14026 sequences in patient 10BR_PE091. After removal
of scaffolding reads not covering the complete V3
region, the coverage dropped from 282 to one read in
subject 10BR_MG029. Overall, 68.9 % of the samples
showed a V3 loop region covered by more than 100
sequencing reads. All MPS reads from the 45 proviral
samples in which a complete V3-loop sequence was
found were submitted to the geno2pheno [coreceptor]
prediction tool. This analysis revealed virus populations
with a pure R5 and ×4 phenotype in 39 (86.7 %) and 5
(11.1 %) blood donors, respectively. The presence of
D/M-tropic sequences was found in one (2.1 %) subject.
Thus, the proportion of all blood donors that harbor
CXCR4-using virus was 13.2 % including the donor with
D/M-tropic viruses. According to the NC, 66.6 % of
sequences predicted as ×4 by geno2pheno showed NC
values ≥ 5; similarly, 95 % of sequences predicted as R5
by geno2pheno had NC values below 5. Regarding the
D/M viruses, the V3 domains sequences displayed NC < 5.The V3 consensus sequences from the 45 samples
were aligned and investigated for the presences of the
GWGR motif in the V3 loop, a feature commonly ob-
served on the Brazilian B subtype samples (Fig. 1). The
tetrapeptide GWGR\AWGR motif in the V3 loop apex
sequence was observed in 5 (11.1 %) donors infected
with pure subtype B and all had predicted R5 viruses.
The aligned sequences were also analyzed for the pres-
ence of A316T and I323V resistance-conferring point
mutations to maraviroc in R5 and D/M viruses The
A316T substitution was detected in 7 (17.9 %) donors,
whereas the I323V substitution was detected in only
three (7.7 %) subjects; both mutations have been shown
to confer maraviroc partial resistance [31]. Phenotypic
assays are necessary to confirm the influence of this
mutation to maraviroc susceptibility. Since maraviroc
was used in Brazil after 2007 on therapy-failure patients,
high rate in treatment-naïve samples may be related to
the transmission of maraviroc-resistant variants from
patients with treatment experience.
Discussion
In this study, we sought to estimate the prevalence of
coreceptor tropism of the archived strains at the time of
primary infection using a total of 45 MPS data from
HIV-1 recently infected Brazilian first-time blood do-
nors. We found 6 ×4 strains (13.3 %) including the D/M
tropic populations (n = 1) and 39 exclusive R5 variants
(86.7 %). The prevalence found for ×4 DNA was similar
to that reported 16.4 %–17.2 % of ×4 and D/M-tropic
strains in recent HIV-1 seroconverter Spanish subjects
[32, 33]. These results were also comparable to those of
Frange et al. [34] who reported a relatively high fre-
quency (15.9 %) of ×4 and D/M virus in 390 HIV-1
subtype-B infected patients diagnosed at the time of pri-
mary infection. Our results were also consistent with
those of a previous study in drug-naive chronically HIV-
infected individuals [35, 36] and in suppressed patients
with a shorter history of viremia suppression [37–39]. In
contrast, our prevalence estimates of CXCR4-using vi-
ruses is higher than those found in 126 recently infected
men having sex with men in the USA study of 3.2 %
[40] and less than the rate of prevalence reported in our
previous study in recently infected Brazilian subjects
(30.2 %) [41]. Factors that might have contributed to the
differences observed were the sample size, type of
samples, the sequencing method, the test replications,
the FPR cutoff, and prediction algorithms used.
The relatively high rate of CXCR4-using viruses in this
study may be explained by the application of deep se-
quencing technology which has improved the prediction
of HIV tropism as has been reported in previous studies
[16, 42, 43]. Using our approach, we were able to detect
one ×4 variant that existed as a mixture along with R5
Table 1 Genetic subtype, coreceptor usage, net charge and sequence coverage across V3 region in PBMC for the HIV-1 isolates












Number of seq. with
charges <5/≥5
10BR_001PE B ×4 322 1.1 132 B 06/126
10BR_003MG BF1 R5 9985 0.7 532 F1 531/01
10BR_003SP B R5 876 1.4 296 B 270/26
10BR_007MG B R5 80 1.3 4 B 04/00
10BR_008SP B R5 655 0.7 120 B 119/1
10BR_009SP B R5 1031 1.0 290 B 271/19
10BR_010MG BCF1 R5 13756 1.0 763 F1 736/27
10BR_010PE B R5 1103 0.8 345 B 330/15
10BR_011SP CRF45_cpx R5 24 0.8 10 A1 10/00
10BR_014SP B R5 404 0.7 176 B 174/02
10BR_015RJ BF1 R5 3687 1.4 818 F1 813/05
10BR_017SP BF1 R5 494 0.4 8 F1 08/00
10BR_017MG BF1 R5 31 0.7 108 F1 108/00
10BR_018PE BC R5 48 0.0 13 B 13/00
10BR_021SP B R5 838 1.0 289 B 288/01
10BR_023RJ BF1 R5/×4 446 1.5 248 F1 248/00
10BR_026RJ BF1 R5 3281 1.1 888 B 48/840
10BR_029MG B ×4 282 0.0 1 B 00/01
10BR_029PE BCF1 ×4 909 0.9 183 F1 06/177
10BR_032RJ B R5 1732 2.0 733 B 733/00
10BR_034MG BF1 R5 844 0.7 51 B 51/00
10BR_034PE B R5 679 0.9 369 B 350/19
10BR_035MG B R5 851 1.2 469 B 462/07
10BR_038SP B R5 2247 1.8 352 B 338/15
10BR_041RJ BF1 R5 342 0.8 160 F1 147/13
10BR_042SP B R5 1269 2.0 293 B 279/14
10BR_043SP B ×4 65 1.7 26 B 006/2020
10BR_045SP B R5 137 0.0 8 B 08/00
10BR_046RJ CRF70_BF1 R5 112 0.4 32 B 32/00
10BR_046SP CF1 R5 2830 2.0 278 C 273/5
10BR_048SP BF1 R5 7 0.0 5 B 05/00
10BR_049SP B R5 632 3.5 44 B 44/0
10BR_050RJ B R5 1695 2.5 341 B 335/06
10BR_050SP B R5 1067 2.2 47 B 35/12
10BR_051RJ B ×4 4301 0.5 482 B 474/08
10BR_053PE B R5 2480 2.0 784 B 750/34
10BR_053RJ BF1 R5 3718 0.9 2011 F1 1888/123
10BR_054RJ B R5 2173 0.9 745 B 655/90
10BR_055SP B R5 1393 1.5 59 B 59/00
10BR_056PE B R5 551 0.5 10 B 00/10
10BR_057SP BF1 R5 2704 0.6 1322 F1 1319/3
10BR_091PE B R5 14026 0.8 2165 B 2161/4
10BR_097PE B R5 3773 3.3 697 B 675/22
10BR_098PE B R5 10215 5.3 1456 B 1311/145
10BR_100PE B R5 6060 3.7 614 B 613/01
1Near Full-Length genomes, 2 False positive rate
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Figure 1 Amino acid alignment of V3 sequences. The consensus sequence from each sample was generated and aligned with HXB2 (Accession
number: K03455). Amino acid positions appear at the top of alignment. Position 316 and 323, corresponding to the third position of the codon
encoding the amino acid at position 11 and 25 of the V3 loop. Dots indicate identities whereas tildes indicate deletions
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based sequencing data had been used alone, we would
have not been able to detect the ×4 variants in that
subject as it presents in 3.2 % of the viral population.
The detection of dual or mixed R5×4 viral strains from
sample collected at the earliest time point could be the
result of concomitant transmission of multiple variants,
or successive infections within a short timeframe. The
assumption of direct transmission of the mixed variants
in subject 10BR_023RJ do not support the hypothesis
of gatekeeping event that almost always selects for trans-
mission of R5 over ×4 HIV-1 strains [44]. Indeed, there
is no convincing evidence has yet been published to proof
the lower transmissibility of ×4 viruses but available datasupport the idea that R5 or D/M infections could result
from a stochastic process [45, 46].
This relatively high prevalence should seriously be
considered when decisions are made about initial regi-
mens for therapy-naive individuals, and HIV-1 co-
receptor usage should be screened before initiation of
any chemokine receptor CCR5 antagonists in clinical
settings. These suggestions are in agreement with the
conclusions of Frange et al. [34] that noted that ×4/DM
strains can fuel the cellular HIV-1 reservoir leading to
viral persistence over a long period complicating future
therapeutic options, including CCR5 antagonists.
One of the major limitations beside the small sample
size of this study is that the assessment of HIV tropism
Pessôa et al. Virology Journal  (2015) 12:74 Page 6 of 7was limited to sequence- based algorithms rather than
using phenotypic methods. Although phenotypic assays
still have an edge over genotypic methods, genotypic
predictors prove to be highly concordant with phenotype
data and can reliably be used to determine viral tropism
with better results in PBMC than in plasma samples
[47]. In this study, we used geno2pheno because it al-
lows for an adjustable cutoff, and it can determine HIV-
1 co-receptor usage in all viral genotypes. This method
has shown a similar performance to the Trofile pheno-
typic assay, the most often used tropism method [48].
Moreover, the method has been shown to achieve higher
sensitivity while retaining high level of specificity when
compared with the performance of different algorithms
[49, 50]. In some samples there were little or no sequen-
cing coverage in the V3 region and this may have biased
the results of this study.
Conclusions
Although the sample size is small and not representative,
our findings add further support to the previous studies
and show that ×4 variants may be frequently found at a
relatively high proportion in early infected subjects.
More studies with large samples size are needed to repli-
cate our findings and to explore the clinical relevance of
the variants with predicted usage of CXCR4 present in
the light of both clinical progression and therapeutic ap-
proach. In conclusion, while suggesting CCR5 antago-
nists (maraviroc) as useful therapeutic approach, it has
to be noted as a caution, that maraviroc resistant R5
strains described in present study were isolated from
non-treated, recently HIV-1 infected individuals.
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